April 26, 2019

Immunotherapy Regimen Gets FDA Approval for Extensive Small Cell Lung Cancer

By SPT Staff
Published Online: Tuesday, Mar 26, 2019

FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer [news release]. Genentech. https://www.gene.com/media/press-releases/14783/2019-03-18/fda-approves-genentechs-tecentriq-in-com. Accessed March 19, 2019.

About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us